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Synthesis of oligodeoxyribonucleotides containing a
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ABSTRACT
Promutagenic O6-alkylguanine adducts in DNA are repaired in
humans by O6-methylguanine-DNA-methyltransferase (MGMT)
in an irreversible reaction. Here we describe the synthesis of a
phosphoramidite that allows the preparation of oligodeoxyri-
bonucleotides (ODNs) containing a novel tricyclic thio ana-
logue of O6-methylguanine in which the third ring bridges the
6-thio group and C7 of a 7-deazapurine. These ODNs are very
poor substrates for MGMT and poorly recognised by the alkyl-
transferase-like protein, Atl1. Examination of the active sites of
both MGMT and Atl1 suggest large steric clashes hindering
binding of the analogue. Such analogues, if mutagenic, are
likely to be highly toxic.
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1. Introduction
The exposure of DNA to alkylating agents can result in the formation of
toxic, pro-mutagenic O6-alkylguanine (O6-alkG) adducts (e.g., Figure 1).
Insertion of thymine opposite O6-alkGs during DNA replication can result
in GC->AT transition mutations, that are a common feature of many
tumours[1] and In humans the protein O6-methylguanine-DNA-methyl-
transferase (MGMT) repairs O6-methylguanine [O6-MeG (1)] and other
O6-alkGs via the irreversible transfer of the alkyl group to Cys145, thereby
reforming guanine and inactivating the protein.[2] During this process the
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damaged base is flipped from the DNA duplex into the protein’s active
site.[3] In humans, the repair of O6-alkGs by MGMT also imparts tumour
resistance to chemotherapeutic agents such as temozolomide and BCNU
(bis-chloroethylnitrosourea).[4] This has led to the development of highly
efficient inhibitors/inactivators of MGMT such as O6-benzylguanine[5] (2)
and O6-(2-bromothenyl)guanine[6] (3) and oligodeoxyribonucleotides
(ODNs) containing these modified bases display IC50 values in the low nM
range.[7,8] However, the ability of MGMT to repair different O6-alkGs
varies considerably. For example, ODNs containing the adducts O6-
(hydroxyethyl)guanine (4)[8] or O6-[4-oxo-4-(3-pyridyl)but-1-yl]guanine
(5)[9], are repaired significantly less efficiently than those containing O6-
MeG. MGMT also repairs ODNs containing O6-alkylguanines within DNA
interstrand crosslinks (ICLs). Such ICLs can be generated following the
reaction of the tricyclic N1,O6-ethanoguanine (6) (Figure 2), derived from
exposure to 1,3-bis[(2-chloroethyl)-1-nitrosourea] with cytosine[10] or fol-
lowing the reaction of DNA with bis electrophiles such as busulfan (1,4-
butanediol dimethanesulfonate)[11] to produce ICLs between O6-alkG and
an adjacent O6-alkG[12] or O4-alkylthymine.[13] The repair of these types of
substrates produces covalent MGMT-DNA complexes. A synthesis of
ODNs containing 6 have been described[14], whilst DNA containing the tri-
cyclic ethanoxanthine 7 (Figure 2) is also repaired by MGMT[15] and is suf-
ficiently stable to allow the chemical synthesis of DNA using standard
phosphoramidite chemistry. ODNs containing 7 have allowed the forma-
tion of covalent MGMT-DNA complexes, enabling structural characterisa-
tion of MGMT-substrate interactions using X-ray crystallography.[3]
In common with MGMT, the highly homologous alkyltransferase-like
(ATL) proteins also recognise O6-alkG adducts in DNA.[16,17] However,
since they lack a nucleophilic Cys (which is typically replaced by Trp or
Ala) they bind to, but do not de-alkylate these adducts. Adduct recognition
by both MGMT and ATL proteins requires flipping of the base adduct into
the active site. Previous structural studies[18,19] reveal that the alkyl binding
pocket in the S.pombe ATL protein, Atl1, is significantly larger than that in
Figure 1. Structures of selected O6-alkylguanine adducts.
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MGMT. Consequently, Atl1 can bind a much wider range of O6-alkG
adducts including many that are poor substrates for MGMT.[19]
Previously, we described[20] syntheses of the tricyclic O6-alkyl-7-deaza-
guanines 8 and 9 (Figure 2), to examine key features of MGMT substrate
recognition. Interestingly we found that ODNs containing compound 8
were completely refractory to repair by MGMT.[21] We reasoned that this
might be due to the locked anti or proximal conformation of the alkyl
group (pointing away from the hydrogen bonding face). This would place
Cys145 in MGMT in an unfavourable trajectory for nucleophilic addition
to the electrophilic carbon attached to the heteroatom. In contrast to 8, the
third ring of 9 is larger and likely more flexible due to the difference in the
C-S vs C-O bond lengths in 9[20] (0.4 Å longer) compared to 8. Previous
studies have revealed that ODNs containing S6-methylthio-6-thioguanine in
addition to those containing O6-methyl-7-deazaguanine are repaired by
MGMT but approximately 450 and 25 times slower respectively than O6-
MeG-containing ODNs.[22] Therefore, we were keen to explore whether
this would allow DNA containing the modified base 9 to react with
MGMT and form a covalent protein-DNA complex. Here we describe the
synthesis of the 20-deoxyribonucleoside of 9, its incorporation into ODNs
and the properties of these ODNs as substrates for both MGMT and Atl1.
2. Results and discussion
2.1. Synthesis of modified oligodeoxyribonucleotides
Earlier studies revealed that the heterocycle 8 was insoluble in aceto-
nitrile[21] which is the preferred solvent for the well-established glycosyla-
tion method involving the reaction of the sodium salt of the purine or
deazapurine with 1-chloro-2-deoxy-3,5-di-O-p-toluoyl-ß-D-ribofura-
nose.[23,24] Consequently the third ring of 8 was constructed after glycosyla-
tion of a suitable precursor.[21] In contrast to 8, compound 9 was fully
soluble in acetonitrile allowing direct glycosylation of the preformed het-
erocycle (Scheme 1). However, following silica column chromatography the
Figure 2. Tricyclic analogues of O6-alkylguanine.
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protected nucleoside product (10) could not be obtained in pure form and
contained small amounts of sugar impurities as evidenced by 1H NMR.
Consequently, the partially purified nucleoside 10 was deprotected by heat-
ing in 1M aq sodium hydroxide. After silica chromatography a pure sam-
ple of the deprotected nucleoside 11 was obtained in 52% overall yield
from 9. The nucleoside 11 was then protected as the formamidine 12,
obtained in 78% yield following reaction with dimethylformamide dimethy-
lacetal in DMF. Compound 12 was then reacted with dimethoxytrityl chlor-
ide to protect the 50-hydroxyl group. Analysis of the product by 1H NMR
indicated that although the 50-OH had been successfully protected, the ami-
dine had decomposed to the corresponding N-formyl compound.
Formamidine protected nucleosides are known to be relatively unstable[25]
whilst we[21] and others[26] have reported on the lability of the formami-
dine protecting group with other O6-alkyl-7-deazaguanine nucleosides, but
have found the N-formyl group to function as a suitable protecting group
during standard automated ODN synthesis.[21,26] The pKa of the N-alky-
lated version of heterocycle 9 is approximately 4.8 compared to around 3.3
for deoxyguanosine and we speculate that the consequent increased basicity
of the amidine 12 makes it more prone to protonation and subsequent
hydrolysis. Phosphitylation of 13 provided the phosphoramidite 14 as a
mixture of two diastereoisomers that were characterised by 31P NMR and
ESI-MS.
Scheme 1. Synthesis of phosphoramidite for incorporation of heterocycle 9 into ODNs. (a) NaH
in CH3CN then 1-chloro-2-deoxy-3,5-di-O-p-toluoyl-ß-D-ribofuranose, 3 hours, rt, (b) NaOH in aq
dioxan, reflux, 1 hour, 47% from 9, (c) Me2NC(OMe)2, DMF, rt, 12 hours, 78%, (d) DMTCl, Et3N,
DMAP, pyridine, rt, 4 hours, 68%, (e) iPr2NPCl(OCH2CH2CN), iPr2EtN, CH2Cl2, rt, 1 hour, 60%.
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The ODNs 50-d(GCCATG9CTAGTA) bearing either a free 50-HO
(ODN-1) or a fluorescent 50-SIMA(HEX) (dichlorodiphenylfluorescein)
label (ODN-2) were then prepared using standard protocols on a DNA
synthesiser but using a 0.15M acetonitrile solution of phosphoramidite 14
(rather than a standard 0.1M solution). “Base-labile” protecting groups
were used for the other bases (phenoxyacetyl for G and A and acetyl for
C). The ODNs were deprotected with 33% aq ammonia at 50 C for
6 hours, then purified by reverse-phase HPLC and characterised by ESI-MS.
2.2. Recognition of modified oligodeoxyribonucleotides by MGMT and Atl1
MGMT repairs O6-MeG in single stranded (ss) or duplex DNA with a
similar efficiency.[27] Therefore we assessed the repair of ss ODN-1 by
MGMT. For this we used the standard assay[28] that involves pre-incuba-
tion of purified recombinant protein with the ODN, followed by the add-
ition of excess DNA containing tritium-labelled O6-MeG. Since the MGMT
reaction is irreversible the residual protein activity can be quantified by
measuring the radioactivity transferred to the protein, allowing IC50 values
to be determined. It should be noted that MGMT repairs The O6-MeG-
containing ODN exhibited an IC50 value of approximately 15 nM
(Figure 3). In contrast, no measurable inactivation of MGMT by ODN1
was observed, in common with both the ODN containing the tricyclic oxy-
gen-containing heterocycle 8 and control (G-containing) ODN. This indi-
cates that MGMT is unable to repair ODNs containing either of the
tricyclic compounds 8 or 9. In addition no evidence for binding of MGMT
to ODN-1 was observed following analysis by polyacrylamide gel electro-
phoresis (data not shown). Pertinent to compound 9 is the fact that
Figure 3. MGMT inactivation data with ODNs indicated.
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MGMT is able to repair ODNs containing S6-methyl-6-thioguanine, and 7-
deaza-O6-methylguanine.[22] It therefore appears that for compound 9 the
lack of repair by MGMT is due to the anti or proximal conformation of
the alkyl substituent attached to the heteroatom. To gain further insight
into the binding of the modified base 9 by MGMT we examined the pub-
lished crystal structure of O6-methylguanine-containing DNA bound to the
catalytically-inactive MGMT-C145S mutant (Figure 4, left). When the base
9 is superimposed into this structure in place of O6-methylguanine, a crit-
ical steric clash between the saturated third ring of the base and Ser157
arises (Figure 4, centre). These results suggest that both binding and the
alkyltransfer reactions are inhibited resulting in the inability of MGMT to
repair DNA containing 9.
Next we examined the ability of Atl1 to recognise the base adduct 9 in
DNA. Since Atl1 binds with very high affinity to O6-alkylguanines in both
ss and duplex DNA[18,19] we assessed its ability to recognise adduct 9 using
ss ODN as previously. Thus, by titrating native, wild-type Atl1 protein into
a solution containing 50-SIMA-(HEX) labelled ODN-2. For the control O6-
MeG containing ODN, we observed a protein-dependent decrease in fluor-
escence from which we derived an equilibrium dissociation constant (Table
1 and Figure 5). Atl1 has a higher affinity for DNA containing 9 compared
to the G-containing sequence, but in common with DNA containing the
oxygen-analogue 8 [21], the affinity is dramatically decreased relative to
ODNs containing O6-MeG. Modelling analogue 9 into the crystal structure
of Atl1 in complex with O6-MeG containing DNA using PyMol (Figure 4,
right) suggests that the saturated ring is in van der Waals contact with the
Figure 4. Left: C145S-MGMT bound to DNA containing O6-methylguanine (PDB file 1T38 [3]);
Centre: C145S-MGMT bound to DNA containing 9 (PDB accession number 1T38 [3] and
CCDC297448 [20]); Right: Atl1 bound to DNA containing 9 (based on PDB file 3GX4 [18] for O6-
methylguanine-containing complex and CCDC297448 [20]). In left and centre panels, Ser145 is
coloured green and Ser157 coloured pink.
Table 1. Equilibrium dissociation constants for Atl1-ODN complexes.
ODN sequence KD (nM)
50-SIMA-d(GCCATGMeGCTAGTA) 2.4 ± 1.2
50-SIMA-d(GCCATG9CTAGTA) 182 ± 5
50-SIMA-d(GCCATG8CTAGTA) 430 ± 41
50-SIMA-d(GCCATGGCTAGTA) 740 ± 91
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main chain amino acid residues in the C-terminal domain of Atl1 which
affects the ability of the protein to bind the DNA.
3. Conclusions
We have prepared ODNs containing a tricyclic thio analogue of O6-methyl-
guanine and shown that with the alkyl group locked in the anti conform-
ation blocks repair by MGMT and severely impedes the binding of Atl1.
Due to the inability of MGMT to repair both compound 9 and previously
described 8[21] we anticipate that these compounds are likely to be muta-
genic and highly toxic unless other mechanisms for their repair such as
BER or NER are possible. We will report on these properties in due course.
4. Experimental
4.1. General methods
Dry solvents were obtained from the University of Sheffield Grubbs appar-
atus. 1-Chloro-2-deoxy-3,5-di-O-p-toluoyl-ß-D-ribofuranose was obtained
from Carbosynth and 2-cyanoethyl-N,N-diisopropyl chlorophosphoramidite
from SigmaAldrich. Column chromatography purifications were carried out
on silica (VWR chemicals, 60–200 mesh) Thin layer chromatography
Figure 5. Fluorescence vs [Atl1] using ODN-2 (5’-SIMA-d(GCCATG9CTAGTA).
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(TLC) was performed on pre-coated Merck silica gel 60 F254 aluminium
backed plates. TLCs were visualised under UV (254 nm). NMR spectra
were recorded on either a Bruker AV250, AV400 or AV500 spectrometer
(individually stated for all data) and chemical shifts are reported in d values
relative to tetramethylsilane as an external standard. J values are given in
Hz. Mass spectrometry was performed by the University of Sheffield Mass
Spectrometry Service using the method of electrospray ionisation on a
Waters LCT Mass Spectrometer unless otherwise stated. Analytical RP-
HPLC was performed on Waters 2695 or 2690 instrumentation using a
Phenomenex Gemini C18 5 lm 4.6 250mm column, flow rate 1mL/min,
UV detection was recorded at 260 nm unless specified otherwise.
Preparative RP- HPLC performed using a Phenomenex Gemini C18 5 lm
110Å 21.2 250mm column at a flow rate of 21mL/min. UV detection
was recorded at 260 nm unless specified otherwise. All quoted retention
times are those found by analytical HPLC.
4.2. Chemical synthesis
NMR Spectra for the compounds synthesised can be found in supplemen-
tary information.
4.2.1. 4-Amino-2-[2-deoxy-3,5-di-O-(p-toluoyl)-b-D-erythro-pentofuranosyl]-6-
thia-7,8,9-trihydro-2,3,5-triazabenzo[cd]azulene (10)
Compound 9 [20] (206mg, 1.0mmol) was dissolved in anhydrous MeCN
(15mL) under Ar at room temp. NaH (44mg, 1.1mmol, 60% in mineral
oil) was added, the mixture stirred for 1 hour then 1-chloro-2-deoxy-3,5-di-
O-p-toluoyl-ß-D-ribofuranose (602mg, 1.4mmol) was added portionwise
over 10minutes. After stirring for 3 hours, the solvent was evaporated and
the product purified by silica column chromatography (eluent 7% EtOAc
in DCM) to give a pale yellow foam (500mg). The nucleoside could not be
obtained free from sugar impurities and was further deprotected (to 11) as
described below.Rf (20% ethyl acetate in DCM) 0.5 (fluorescent at 356 nm).
1
H NMR (250.13MHz, CDCl3) dH 8.02-7.95 (m, 4H), 7.32-7.26 (m, 4H),
6.74 (s, 1H), 6.68 (dd, 1H, J¼ 3.4Hz, 5.5Hz), 5.76-5.72 (m, 1H), 5.02 (s,
2H), 4.78-4.72 (m, 1H), 4.62-4.55 (m, 2H), 3.12-3.09 (m, 2H), 2.84-2.76 (m,
1H), 2.67-2.60 (m, 1H), 2.46 (s, 3H), 2.45 (s, 3H), 2.30-2.27 (m, 2H) ppm
13
C NMR (100.62MHz, CDCl3) dC 166.26, 166.06, 163.30, 157.45, 151.67,
144.40, 144.07, 129.83, 129.70, 129.25, 126.98, 126.65, 117.82, 115.71,
110.27, 83.11, 81.83, 75.27, 64.30, 39.35, 31.03, 29.54, 28.55, 21.70 ppm HR
ES-MS m/z calcd for C30H31N4O5S [MþH]
þ 559.2015, found 559.2021.
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4.2.2. 4-Amino-2-(2-deoxy-b-D-erythro-pentofuranosyl)-6-thia-7,8,9-trihydro-
2,3,5-triazabenzo[cd]azulene (11)
Compound 10 (500mg, 895 mmol) was dissolved in 1,4-dioxane (6mL) and
1M aq NaOH solution was added (3mL, 3mmol). The mixture was then
refluxed at 90 C for 1 hour, cooled to r.t. and neutralised with 0.1M acetic
acid aqueous solution. The mixture was evaporated, and the residue puri-
fied by silica column chromatography (eluent 60% acetone in DCM) to
obtain a pale yellow solid (150mg, 466 mmol, 47% from 9). Rf (20% MeOH
in DCM) 0.28 (fluorescent spot using 356 nm) 1H NMR (500.13MHz, d6-
DMSO) dH 7.00 (s, 1H), 6.42 (dd, 1H, J¼ 3.4Hz, 5.5Hz), 6.16 (s, 2H), 5.19
(d, 1H, J¼ 4.5Hz), 4.87 (t, 1H, J¼ 5.6Hz), 4.29-4.25 (m, 1H), 3.75-3.73 (m,
1H), 3.51-3.43 (m, 2H), 3.07 (t, 2H, J¼ 6.0Hz), 2.85 (t, 2H, J¼ 7.6Hz),
2.36-2.30 (m, 1H), 2.13 (m, 2H), 2.07-2.02 (m, 1H) 13C NMR (125.76MHz,
d6-DMSO) dC 165.16, 158.13, 152.55, 117.76, 117.76, 114.10, 109.41, 86.82,
81.47, 71.02, 62.06, 39.84, 31.41, 29.96, 29.03; HR ES-MS m/z calcd for
C14H19N4O3S [MþH]
þ 323.1178, observed 323.1183.
4.2.3. 4-{[(Dimethylamino)methylidene]amino}-2-(2-deoxy-b-D-erythro-pentofur-
anosyl)-6-thia-7,8,9-trihydro-2,3,5-triazabenzo[cd]azulene (12)
Compound 11 (140mg, 435lmol) was dissolved in anhydrous DMF
(2mL), under Ar at room temperature. After 1 hour, N,N-dimethylforma-
mide dimethylacetal (0.5mL, 3.5mmol) was added and the solution left to
stir overnight. After evaporation the residue was purified by silica column
chromatography (eluent 0-5% MeOH in DCM (containing 1% triethyl-
amine)) to give a white foam (128mg, 78%). Rf (20% MeOH in DCM) 0.35
1
H NMR (249.87MHz, CD3OD) dH 8.63 (s, 1H), 7.20 (s, 1H), 6.67 (dd,
1H, J¼ 8.0Hz, 6.1Hz), 4.49 (m, 1H), 3.95 (m, 1H), 3.73 (m, 2H), 3.25 (m,
1H), 3.18 (s, 3H), 3.16 (m, 2H), 3.12 (s, 3H), 2.98 (m, 2H), 2.60 (m,1H),
2.34 (m, 3H). 13C NMR (100.62MHz, CD3OD) dC 164.49, 158.44, 156.66,
150.30, 118.99, 113.23, 111.55, 85.49, 81.53, 69.98, 60.71, 38.40, 38.03,
32.55, 30.39, 28.54, 27.35. HR ES-MS m/z calcd for C17H24N5O3S
[MþH]þ 378.1600, observed 378.1603
4.2.4. 4-{[(Formylamino}-2-(2-deoxy-5-O-[4,4’-dimethoxytrityl]-b-D-erythro-pen-
tofuranosyl)-6-thia-7,8,9-trihydro-2,3,5-triazabenzo[cd]azulene (13)
Compound 12 (100mg, 265lmol) was dissolved in anhydrous pyridine
(5mL) under Ar with stirring at room temperature. Triethylamine (0.5mL,
340 lmol) , 4,4-dimethoxytrityl chloride (109mg, 318 lmol) and 4-N,N-
dimethylaminopyridine (2mg, 15 lmol) were added. After 4 hours the mix-
ture was evaporated, redissolved in EtOAc (20mL) and washed with water
(10mL), brine (10mL) and dried (Na2SO4). Evaporation and purification
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of the resulting residue by silica column chromatography (0-5% MeOH/
DCM (1% Et3N)) gave 13 as a pale yellow foam (117mg, 68%). Rf (10%
MeOH in DCM) 0.35 1H NMR d (249.87MHz, CD3OD) dH 9.41 (s, 1H),
8.54 (d, 1H), 7.43–7.15 (m, 14H), 6.65 (t, 1H, J¼ 6.6Hz), 4.64 (m, 1H),
4.05 (m, 1H), 3.77 (s, 6H), 3.32 (m, 3H), 3.12 (m, 2H), 2.75–2.64 (m, 3H),
2.41 (m, 1H), 2.18 (m, 2H). 13C NMR (100.62MHz, CD3OD) dC 166.54,
163.17, 158.50, 150.64, 150.27, 149.13, 144.67, 135.80, 135.69, 130.17,
130.13, 128.25, 127.79, 120.85, 115.01, 114.57, 113.06, 106.57, 86.45, 86.08,
82.94, 71.54, 63.98, 55.17, 46.16, 46.07, 40.80, 38.99, 32.47, 29.88, 29.12,
11.35. HR ES-MS (ESI) m/z calcd for C36H37N4O6S [MþH]
þ 653.2434,
observed 653.2458
4.2.5. 4-[(Formyl)amino)-2-[2-deoxy-3-(2-cyanoethyl-N,N-diisopropylaminophos-
phoryl-5-O-(4,4’-dimethoxytrityl))-b-D-erythro-pentofuranosyl)]-6-thia-
7,8,9-trihydro-2,3,5-triazabenzo[cd]azulene (14)
Compound 17 (110mg, 168 lmol) was dissolved in dry DCM (2mL) under
Ar at room temperature. Dry N,N-diisopropyl ethylamine (116 lL,
672 lmol) was then added followed by the dropwise addition of 2-cya-
noethyl-N,N-diisopropyl chlorophosphoramidite (48lL, 200 lmol) over
15minutes. After 1 hour benzyl alcohol solid support (2.5mmol/g average)
was added[29] and the resulting suspension was stirred for 30minutes fur-
ther. The reaction was then filtered to remove the solid support, the filtrate
was washed with 10% Na2CO3 (10ml), brine (10mL) and dried (Na2SO4).
The residue was evaporated and purified by silica gel column chromatog-
raphy under nitrogen eluting with 45% dichloromethane/hexane (contain-
ing 10% triethylamine) to give phosphoramidite 14 as a white foam (85mg,
60%). Rf (EtOAc/hexane/Et3N, 45:45:10¼ 0.55, 0.57;
31
P NMR (CDCl3) dP
þ148.84, þ148.78 ppm; 1H NMR (249.87MHz, CDCl3) dH 9.48 (d, 1H),
7.80 (m, 1H). 7.46-6.79 (m, 14H), 6.65 (t, 1H, J¼ 7Hz), 4.74 (m, 1H), 4.23
(m, 1H), 3.78 (s, 6H), 3.75 (m, 4H), 3.30 (m, 2H), 3.12 (m, 2H), 2.76 (m,
2H), 2.64 (m, 3H), 2.26 (m, 2H), 2.02 (bs,2H), 1.22 (d, 12H) HR ES-MS
m/z calcd for C45H54N6O7PS [MþH]
þ 853.3512, observed 853.3486
4.3. Oligodeoxyribonucleotide (ODN) synthesis
The ODNs 50-d(GCCATG9CTAGTA) bearing either a 50-OH (ODN-1) or
a 50- dichlorodiphenylfluorescein (SIMA(HEX)) label (ODN-2) were syn-
thesised on an Applied Biosystems DNA automated synthesiser (Model
394) employing “base labile” phosphoramidites (pac-A, iPr-pac-G and Ac-
C) from Link Technologies and the phosphoramidite for the 50-SIMA label
from Glen Research. The coupling efficiency for the phosphoramidite 14
(based on trityl cation measurement) was 98%. After synthesis, the ODNs
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were removed from the solid support with 33% aq ammonia solution at
room temperature by the Applied Biosystems 394 automated synthesiser
through the machine’s own deprotection programme. Further incubation at
room temperature overnight removed the N-formyl and other protecting
groups. The deprotected oligomers were purified by reverse phase high per-
formance liquid chromatography (RP-HPLC) using a Hichrom ACE-5 C18
(250 4.6mm) column with a flow rate of 1mL/minute and detection at
260 nm and a gradient of 0 - 60% B in 30minutes (A¼ 0.1M triethylam-
monium bicarbonate pH 7.5/5% CH3CN, B¼CH3CN). Fractions contain-
ing purified ODNs were evaporated, redissolved in water, de-salted using a
NAP-10 gel filtration column (GE Healthcare) to give 286 nmol of ODN-1
and 231 nmol of ODN-2. ODNs were characterised using ES-MS. ODN-1
had an HPLC retention time of 14.9minutes and ES-MS-ve calcd. 4030,
found. 4030 [M-H]-. ODN-2 HPLC had a retention time of 18.2minutes
and ES-MS -ve calcd. 4788, found 4788 [M-H]-.
4.4. MGMT assays
The inactivation of recombinant human MGMT by the modified ODN-1
involved pre-incubation of MBP-MGMT (MGMT fusion with maltose
binding protein) with varying amounts of ODN for 10 hours at 37 C using
the procedure described previously.[28]
4.5. Binding assays with Atl1
Fluorescence emission intensity measurements (determined in triplicate)
used a 1 nM solutions of 50-ODNs in 1mL of titration buffer (50mM
Tris–HCl pH 7.5, 50mM NaCl, 1mM EDTA) to which were added native
Atl1.[19] The binding isotherms were fitted by non-linear least-squares
regression using KaleidaGraph to the following equation describing the
equilibrium DþE $ DE (where D¼ODN, E¼ enzyme, DE¼ODN-
enzyme complex)
I¼ Imax þ [(DþE þ KD) – ((DþE þ KD)
2
– (4DE)) 0.5] (Imin – Imax)/
2D (where I¼ intensity measured at a certain concentration of enzyme,
Imax ¼ maximum intensity (i.e., prior to protein addition), Imin ¼ min-
imum intensity (i.e., when binding is saturated), D¼ODN concentration,
KD ¼ dissociation constant).
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